To this end, an extreme phenotype test was performed for a genome-wide association study in 166 patients, which revealed that the skin of the patient with severe HFS showed low levels of R-cadherin and Involucrin (proteins that are essential for the structure and function of the skin barrier) before treatment with capecitabine. The gene discussed is CDH4; the disease is Hand-foot syndrome.